Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study

NCT05029466 is registered in ClinicalTrials.gov with Brain and Cognition Discovery Foundation as lead sponsor.

NCT NCT05029466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study
Lead sponsor
Brain and Cognition Discovery Foundation
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2021
Completion date
July 22, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression